Clinical trial
A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA)…
NCT00316771 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00316771 |
|---|---|
| Title | A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy |
| Official title | A Randomized, Double-blind, Placebo-controlled, Study to Determine the Efficacy and Safety of 5 Dose Regimens of RO4402257 in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | P38 Inhibitor (4) 150mg, P38 Inhibitor (4) 25mg, P38 Inhibitor (4) 300mg, P38 Inhibitor (4) 50mg, P38 Inhibitor (4) 75mg, Placebo |
| Enrollment | 374 |
| Start date | Nov 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Apr 21, 2006 |
| Last update posted | Nov 2, 2016 |
| Countries | Australia, Brazil, Canada, Estonia, Germany, Greece, Ireland, Mexico, New Zealand, Poland, South Africa, Spain and 2 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: